BARRX Medical Company

BARRX Medical, Inc. develops endoscopic treatment solutions for Barrett's esophagus and other chronic gastroenterological diseases. Barrett's is a precancerous condition of the lining of the esophagus (swallowing tube) caused by gastroesophageal reflux disease, or GERD. The company's HALOFLEX, HALO360 and HALO90 ablation systems are designed to provide a uniform and controlled ablation effect, in order to remove diseased tissue and allow re-growth of normal cells.
Technology: Precision Medicine
Industry: P4 Medicine
Headquarters: United States
Founded Date: 2003
Employees Number: 51-100
Funding Status: M&A
Investors Number: 6
Total Funding: $42.8M
Last Funding Type: Series D

Visit Website
http://twitter.com/barrxmedical
Register and Claim Ownership